Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?

Purpose of Review Drug-eluting stents are used in nearly all cases of percutaneous coronary revascularization and have been shown to be superior to balloon angioplasty or bare metal stents. The designs of these stents are continually evolving to maximize efficacy and safety. Recent Findings This review outlines the important components of a drug-eluting stent and highlights the changes in stent design that have led to the optimization of clinical outcomes. Most stents used in contemporary times are thin strut, durable polymer drug-eluting stents (DES) that elute either everolimus or zotarolimus. Newer DES designs incorporating bioresorbable polymers or ultrathin struts have shown encouraging safety and efficacy profiles. DES are essential for the management of patients with obstructive coronary artery disease and are used in most coronary interventions. Changes in stent designs over the past 30 years reflect the ongoing need to address the limitations of earlier stents aimed to improve patient outcomes.

Automated summary

Drug-eluting stents are widely used in coronary revascularization and have been proven to be superior to other treatments. The design of these stents is constantly improving to enhance clinical outcomes and safety. The incorporation of bioresorbable polymers or ultrathin struts in newer designs has shown promising results in terms of safety and efficacy.